[Lysophosphatidic acid in ovarian cancer patients]
- PMID: 16956044
[Lysophosphatidic acid in ovarian cancer patients]
Abstract
Objective: To compare plasma lysophosphatidic acid (LPA) level in ovarian cancer patients and women without ovarian pathology.
Design: Prospective study.
Setting: Department of Gynecology and Obstetrics, University Hospital, Hradec Králové.
Methods: The method for LPA level analyze with its specification by capillary electrophoresis using indirect ultraviolet detection has been implementated. Since the beginning of this project venous blood samples from 103 patients (60 patients with ovarian cancer, 43 patients without ovarian pathology) have been obtained.
Results: Plasma LPA levels were elevated in ovarian cancer patients (sigma LPA Med 19.9 micromol/l, Range 4.5-42.7 micromol/l). Patients without ovarian pathology (n=35) (sigma LPA Med 2.6 micromol/l, Range 0.9-22.9 micromol/l, P<0,001) had statistically significant lower plasma LPA level compared with ovarian cancer patients.
Conclusion: Lysophosphatidic acid appears useful as diagnostic marker of ovarian cancer.
Similar articles
-
Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.Tumour Biol. 2011 Apr;32(2):311-6. doi: 10.1007/s13277-010-0123-8. Tumour Biol. 2011. PMID: 21061112
-
Lysophosphatidic acid: an ovarian cancer marker.Eur J Gynaecol Oncol. 2008;29(5):511-4. Eur J Gynaecol Oncol. 2008. PMID: 19051824
-
Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.JAMA. 1998 Aug 26;280(8):719-23. doi: 10.1001/jama.280.8.719. JAMA. 1998. PMID: 9728644
-
Methods for quantifying lysophosphatidic acid in body fluids: a review.Anal Biochem. 2014 May 15;453:38-43. doi: 10.1016/j.ab.2014.02.021. Epub 2014 Mar 5. Anal Biochem. 2014. PMID: 24613261 Review.
-
Preclinical detection of lysophosphatidic acid: A new window for ovarian cancer diagnostics.Talanta. 2022 Sep 1;247:123561. doi: 10.1016/j.talanta.2022.123561. Epub 2022 May 17. Talanta. 2022. PMID: 35609485 Review.
Cited by
-
Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.Tumour Biol. 2011 Apr;32(2):311-6. doi: 10.1007/s13277-010-0123-8. Tumour Biol. 2011. PMID: 21061112
-
Lysophosphatidic acid activates the RhoA and NF-κB through Akt/IκBα signaling and promotes prostate cancer invasion and progression by enhancing functional invadopodia formation.Tumour Biol. 2016 May;37(5):6775-85. doi: 10.1007/s13277-015-4549-x. Epub 2015 Dec 10. Tumour Biol. 2016. PMID: 26662305
-
An extremely simple method for extraction of lysophospholipids and phospholipids from blood samples.J Lipid Res. 2010 Mar;51(3):652-9. doi: 10.1194/jlr.D001503. Epub 2009 Sep 25. J Lipid Res. 2010. PMID: 19783525 Free PMC article.
-
Measurement of phospholipids may improve diagnostic accuracy in ovarian cancer.PLoS One. 2012;7(10):e46846. doi: 10.1371/journal.pone.0046846. Epub 2012 Oct 17. PLoS One. 2012. PMID: 23082132 Free PMC article.
-
Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside.Cancers (Basel). 2019 Oct 10;11(10):1523. doi: 10.3390/cancers11101523. Cancers (Basel). 2019. PMID: 31658655 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous